A Multicenter, Randomized, Placebo-Controlled, "Factorial" Design, 12-Month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day co-Administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia.

Trial Profile

A Multicenter, Randomized, Placebo-Controlled, "Factorial" Design, 12-Month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day co-Administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Atorvastatin; Canosimibe
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2009 Actual patient number (1736) added as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top